Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
about
Lupus nephritis: current updateTreatment for lupus nephritisTreatment for lupus nephritisLupus Nephritis: A Different Disease in European Patients?Lupus Nephritis in Asia: Clinical Features and ManagementCurrent and emerging treatment options in the management of lupusThe Efficacy and Safety of Leflunomide for the Treatment of Lupus Nephritis in Chinese Patients: Systematic Review and Meta-AnalysisUpdate on mesenchymal stem cell-based therapy in lupus and sclerodermaNon-invasive imaging to monitor lupus nephritis and neuropsychiatric systemic lupus erythematosusLupus nephritis: the evolving role of novel therapeuticsA treatment algorithm for children with lupus nephritis to prevent developing renal failureCrossing the Atlantic: the Euro-Lupus Nephritis regimen in North AmericaIn vivo, multimodal imaging of B cell distribution and response to antibody immunotherapy in miceInfection in systemic lupus erythematosus, similarities, and differences with lupus flare.Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada StudyRheumatic autoimmune diseases in women and midlife healthEarly change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysisCurrent status of lupus nephritis.Recent clinical trials in lupus nephritis.Association between low-dose pulsed intravenous cyclophosphamide therapy and amenorrhea in patients with systemic lupus erythematosus: a case-control study.Cyclophosphamide and lupus nephritis: when, how, for how long?Efficacy of two cyclophosphamide regimens for the treatment of lupus nephritis in Puerto Ricans: low vs. standard dose.Is newer safer? Adverse events associated with first-line therapies for ANCA-associated vasculitis and lupus nephritis.Unexpected recovery from longterm renal failure in severe diffuse proliferative lupus nephritis.Kidney transplantation in patients with systemic lupus erythematosus.Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial.Role of early repeated renal biopsies in lupus nephritis.Belimumab for the treatment of systemic lupus erythematosus.Efficacy of long-term maintenance therapy with mycophenolate mofetil in lupus nephritis.Systemic lupus erythematosus: review of synthetic drugs.Variability of the impact of adverse events on physicians' decision makingLupus nephritis: a 15-year multi-centre experience in the UK.Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: a long-term observational prospective study.Renal involvement in autoimmune connective tissue diseases.Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritisEvaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy.Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006.Early change in proteinuria as a surrogate outcome in kidney disease progression: a systematic review of previous analyses and creation of a patient-level pooled dataset.ESRD from lupus nephritis in the United States, 1995-2010IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment.
P2860
Q22000837-062A3792-8D5A-4FE9-BF1D-E41ED714D4C3Q24202572-9C01DD87-E84B-4876-A360-3C946C9826B7Q24247408-E6AF5964-2E5E-41CB-A5A8-69F1D68458E9Q26740483-96EA2074-A406-44BB-B07F-0C770945DA8BQ26740487-7645B490-E0F0-47E3-89C7-B9EDAC7DE99BQ26741266-EF795723-3940-4118-916E-34C4B7180D85Q26775707-5510A9F9-27FD-4F99-B94D-4775A07122AEQ26777402-17B20139-F79B-4CD9-882D-BC65A652B433Q26796871-B115D426-7B2E-4C0C-B5BF-5D3B00594807Q26998390-3F7F8A07-487D-41DE-B465-3733DB6421C2Q27026880-696F3193-AA21-4934-9AE2-B50459B267DBQ28645743-5AC029B8-4DF2-4796-9B10-4ED1A81458C5Q28752150-755A1E4C-3E58-454A-90ED-C8A0982D932BQ33690722-3226D51A-1BBB-4AB1-8425-485BAB5512DFQ33695128-848A2F89-893C-4348-8D94-63E564D32184Q33727015-404CD235-DFDA-4659-B473-069C108A86BBQ33805412-9A54F186-55A7-4BCF-B633-FB1713E93C0EQ33882751-E0FE98B4-44C8-4F26-BA22-3FE05C1F0601Q33924437-16202F86-26B0-4CA8-95F6-5923C93980EDQ33929673-DD3F5662-FA4A-43AC-AFCE-CB773D78ADBBQ34095231-030E5E30-8313-42CB-B43E-6C0237CE9BA5Q34118894-315F1181-1ED6-4FD3-9D43-69AE7AD1426DQ34124711-4895F6A3-9955-46AA-BD88-D137F93C252DQ34367705-24309897-C436-48FA-93C3-093F15D7CE84Q34397379-84832DA7-21E8-4B22-8DE5-F28605DF2799Q34409787-C0E1778F-A890-4409-A8C6-9EB45A3AEF17Q34424633-B2C4A4B6-AC21-461C-B935-C1A0B0B32676Q34455827-8260E88D-A439-4FBA-AAF8-A3E1048C35D8Q34490782-E3687BD2-B88D-40E1-9068-35046826E136Q34498515-948756B4-348E-4006-B0DC-0FA9322C70DBQ34538062-2572A681-2301-4860-BF4B-5040A634B06FQ34578139-C154346C-82AC-4243-970D-0556C94AFA33Q34613945-1C0B7DEA-6F95-4BAB-A574-524169F755F4Q34654954-D026A7DC-986D-469E-B1D3-69DF6B3EEC86Q34975939-81D31511-A1CD-44E1-A806-90AC46C2FAE0Q35008162-A0B69838-9688-4395-B72A-84BEC9E7FB6EQ35019423-ECFE633F-E80B-4AB8-A697-810D0E9AC291Q35025425-D3E4BC7E-CB8A-4DD6-A50D-1CFA671182A1Q35051164-7489E913-09CC-4F2A-8148-0DCE40FF9DC1Q35078183-715326E4-22F9-4B3E-B88E-BFD9B0B1DF76
P2860
Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Immunosuppressive therapy in l ...... intravenous cyclophosphamide.
@en
Immunosuppressive therapy in l ...... intravenous cyclophosphamide.
@nl
type
label
Immunosuppressive therapy in l ...... intravenous cyclophosphamide.
@en
Immunosuppressive therapy in l ...... intravenous cyclophosphamide.
@nl
prefLabel
Immunosuppressive therapy in l ...... intravenous cyclophosphamide.
@en
Immunosuppressive therapy in l ...... intravenous cyclophosphamide.
@nl
P2093
P2860
P50
P356
P1476
Immunosuppressive therapy in l ...... intravenous cyclophosphamide.
@en
P2093
Alessandro Mathieu
Daniel Abramovicz
Daniel Blockmans
David D'Cruz
Enrique de Ramon Garrido Ed
Frédéric A Houssiau
Geneviève Depresseux
Gian Domenico Sebastiani
Haner Direskeneli
P2860
P304
P356
10.1002/ART.10461
P577
2002-08-01T00:00:00Z